A Phase 2 interventional study of Ascorbic acid and Placebo in Chronic Rhinosinusitis, Intraoperative Bleeding and Blood Loss, Surgical, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Assiut University · Phase 2, Interventional, and Prevention
Functional endoscopic sinus surgery (FESS), or sinusoscopy, is a standard surgical procedure used to treat chronic rhinosinusitis and other conditions of the nasal sinuses. However, bleeding during surgery is a frequent challenge that can obstruct the surgeon's view, lengthen operative time, and increase the risk of complications.
Vitamin C (ascorbic acid) supports collagen synthesis, capillary wall strength, and blood vessel integrity, which may help minimize mucosal bleeding during surgical procedures.
The purpose of this randomized clinical trial is to evaluate whether administering preoperative Vitamin C reduces intraoperative bleeding, enhances surgical field visibility, and shortens operative duration in adult patients undergoing elective sinusoscopy.
Participants will be randomly assigned to one of two groups:
Total blood loss will be recorded during surgery, surgical field clarity will be evaluated every 15 minutes using the Boezaart scale, and participants will be monitored for postoperative bleeding and potential side effects for up to 48 hours.
218 studies on the registry are indexed under Blood Loss, Surgical; 39 are open to participants now.
This study's planned enrollment of 78 is below the median of 90 across 157 interventional studies indexed under Blood Loss, Surgical.
Browse Blood Loss, Surgical studies →Assiut University is the lead sponsor of 4,916 studies on the registry; 2,113 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients scheduled for elective functional endoscopic sinus surgery (FESS) receiving a standardized dose of 500 mg Vitamin C (ascorbic acid) preoperatively in addition to standard general anesthesia and monitoring.
Drug: Ascorbic acid
Patients scheduled for elective functional endoscopic sinus surgery (FESS) receiving matching placebo or standard perioperative care preoperatively in addition to standard general anesthesia and monitoring.
Other: Placebo
Administration of a standardized dose of 500 mg Vitamin C (ascorbic acid) preoperatively prior to functional endoscopic sinus surgery (FESS).
Also known as: Vitamin C
Administration of matching placebo or standard perioperative care preoperatively prior to functional endoscopic sinus surgery (FESS).
Total Intraoperative Blood Loss
Total intraoperative blood loss measured in milliliters (mL). Calculated as the total fluid collected in the suction canisters minus the volume of surgical irrigation fluid used, added to the volume calculated from blood-soaked gauzes (determined gravimetrically: wet gauze weight minus dry gauze weight, where 1 g = 1 mL).
Time frame: Through completion of surgery, up to 2 hours
No study locations are listed for this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University